Results 41 to 50 of about 29,074 (242)

Bispecific antibodies in cancer immunotherapy [PDF]

Current Opinion in Biotechnology, 2020
Among antibody-based cancer therapies, bispecific antibodies (biAbs) have gained momentum in preclinical and clinical investigations following the regulatory approvals of the trailblazing T-cell engaging biAb (T-biAb) blinatumomab. Discussed herein are recent strategies that aim at boosting the potency and mitigating the toxicity of T-biAbs, broadening
openaire   +2 more sources

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Advances in Therapy of Adult Patients with Acute Lymphoblastic Leukemia

Cells
The landscape of adult acute lymphoblastic leukemia (ALL) is dramatically changing. With very promising results seen with novel immunotherapeutics in the setting of relapsed and refractory disease, the prospect of using these agents in first-line therapy
Oscar Sucre, Saagar Pamulapati, Zeeshan Muzammil, Jacob Bitran   +3 more
doaj   +1 more source

Multivalent Anchoring and Oriented Display of Single-Domain Antibodies on Cellulose

Sensors, 2009
Antibody engineering has allowed for the rapid generation of binding agents against virtually any antigen of interest, predominantly for therapeutic applications.
Roger MacKenzie, Jamshid Tanha, Yan Luo, Linda Veldhuis, J. Christopher Hall, Greg Hussack   +5 more
doaj   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer

Antibodies, 2016
Bispecific antibodies offer a promising approach for the treatment of cancer but can be challenging to engineer and manufacture. Here we report the development of PF-06671008, an extended-half-life dual-affinity re-targeting (DART®) bispecific molecule ...
Adam R. Root, Wei Cao, Bilian Li, Peter LaPan, Caryl Meade, Jocelyn Sanford, Macy Jin, Cliona O’Sullivan, Emma Cummins, Matthew Lambert, Alfredo D. Sheehan, Weijun Ma, Scott Gatto, Kelvin Kerns, Khetemenee Lam, Aaron M. D’Antona, Lily Zhu, William A. Brady, Susan Benard, Amy King, Tao He, Lisa Racie, Maya Arai, Dianah Barrett, Wayne Stochaj, Edward R. LaVallie, James R. Apgar, Kristine Svenson, Lidia Mosyak, Yinhua Yang, Gurunadh R. Chichili, Liqin Liu, Hua Li, Steve Burke, Syd Johnson, Ralph Alderson, William J. J. Finlay, Laura Lin, Stéphane Olland, William Somers, Ezio Bonvini, Hans-Peter Gerber, Chad May, Paul A. Moore, Lioudmila Tchistiakova, Laird Bloom   +45 more
doaj   +1 more source

CD3ɛ Nanobody‐Engineered Extracellular Vesicles Driving In Vivo Generation of TCE‐secreting CAR‐Ts for Solid Tumor Therapy With Memory Response and Minimal Immunogenicity

Advanced Science, EarlyView.
HEK‐293T‐derived CD3ε Nb‐engineered EVs to generate dual‐targeting CAR‐T cells directly in vivo. These EVs selectively deliver CAR.BiTE transgenes into T cells and reprogramed to HLA‐G/PD‐L1‐targeting effector cells with enhanced memory and persistence.
Shi‐Wei Huang, Yu‐Chuan Lin, Chih‐Ming Pan, Yeh Chen, Ming‐You Shie, Cheng‐Yu Chen, Kai‐Wen Kan, Yi‐Wen Chen, Ming‐Chao Liu, Chung‐Chun Wu, Yu‐Ting Chiang, Huai‐Ping Ho, Chen‐Yu Lin, Pei‐Ying Lin, Yu‐Han Huang, Steffany Rusli, Wan‐Yu Mao, Pei‐Wen Huang, Sin‐Ting Wang, Wan‐Chen Tsai, Ya‐Hsu Chiu, Ting‐Hsun Lin, Wan‐Ling Chiang, Che‐Kai Chang, Zi‐Lun Lai, Mei‐Chih Chen, Shao‐Chih Chiu, Der‐Yang Cho   +27 more
wiley   +1 more source

PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy

Advanced Science, EarlyView.
The PBAP‐gE complex anchors gE antigen to PD‐L1 on tumor cells. Vaccine‐induced anti‐gE antibodies simultaneously engage FcγRIIIa on NK cells and tumor‐bound PBAP‐gE, triggering NK cell activation and antibody‐dependent cellular cytotoxicity, thereby selectively eliminating PD‐L1–expressing tumor cells.
Huixin Gao, Lijuan Lu, Xiaoxiao Xiong, Yi Li, Donghui Hu, Duo Zhang, Zhiwei Feng, Cong Liu, Nannan Liu, Xiaoli Li, Jizhou Tan, Ting Liu, Ling Peng, Lu Lu, Huiyi Feng, Yan Zhong, Guisen Tan, Zhicheng Zhang, Liqin Huang, Chao Su, Ying Xue, Shuo Song, Wenxia Fan, Wei Wang, Fan Zou   +24 more
wiley   +1 more source

COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors

mAbs, 2020
Conditionally active COBRA™ (COnditional Bispecific Redirected Activation) T cell engagers are engineered to overcome the limitations of inherently active first-generation T cell engagers, which are unable to discern between tumor and healthy tissues ...
Anand Panchal, Pui Seto, Russell Wall, Brian J. Hillier, Ying Zhu, Jessica Krakow, Aakash Datt, Elizabeth Pongo, Andisheh Bagheri, Tseng-Hui T. Chen, Jeremiah D. Degenhardt, Patricia A. Culp, Danielle E. Dettling, Maia V. Vinogradova, Chad May, Robert B. DuBridge   +15 more
doaj   +1 more source

Bispecific Antibody-Functionalized Upconversion Nanoprobe [PDF]

Analytical Chemistry, 2018
Upconversion nanoparticles (UCNPs) are new optical probes for biological applications. For specific biomolecular recognition to be realized for diagnosis and imaging, the key lies in developing a stable and easy-to-use bioconjugation method for antibody modification.
Hao He, Christopher B. Howard, Yinghui Chen, Shihui Wen, Gungun Lin, Jiajia Zhou, Kristofer J. Thurecht, Dayong Jin   +7 more
openaire   +3 more sources